# Ipamorelin Dosage in Research: Doses, Routes and Half-Life > Ipamorelin dosage in the research record — the doses, routes, and ~2-hour half-life documented in studies, third person and study-attributed. No human dosing recommendations. This page records doses and routes exactly as published, for context. It is not a protocol, and it contains no recommendation for human use. ## The short version There is no established human dose of ipamorelin, because ipamorelin is not an approved medicine [3]. What exists are the specific amounts that specific studies gave to specific subjects — and those are reported here as history, not instruction. In the one human pharmacokinetic study, volunteers received single intravenous infusions; the drug cleared with a half-life of about 2 hours [2]. In the failed surgery trial, patients got 0.03 mg/kg into a vein twice a day [3]. Animal studies used a range of doses by injection [4][5]. None of these is a recommendation, and this page deliberately gives no "how much to take" guidance — that would be both unsafe and outside what the evidence supports. The numbers are here so you can see exactly what was tested. ## Doses recorded in the studies The doses below are administered doses from published studies, given in third person. They are not converted into human protocols. - **Human pharmacokinetic study:** single intravenous infusions of 4.21–140.45 nmol/kg over 15 minutes [2]. - **Human Phase 2 ileus trial:** 0.03 mg/kg intravenously twice daily for up to 7 days [3]. - **Rat bone-growth study:** 18, 90, and 450 µg/day subcutaneously, divided three times daily, for 15 days [4]. - **Ferret cachexia study (2024):** 1–3 mg/kg intraperitoneally [5]. A recurring theme across these is that the human work used intravenous dosing under study conditions, while the dominant route in real-world research use — subcutaneous self-administration — has no published human pharmacokinetic or safety characterization at all [3]. ## Half-life and clearance In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours after intravenous dosing, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is a single discrete pulse, peaking about 40 minutes after the dose and then subsiding [2]. The short half-life is the pharmacological reason ipamorelin is described as producing a pulse rather than a sustained elevation. It is also why the molecule, in research settings, was studied with repeat dosing rather than a single daily exposure — though, again, no human dosing schedule is endorsed here [2]. ## Routes studied The routes appearing in the ipamorelin literature are all parenteral for the parent peptide. Intravenous dosing carries the human pharmacokinetic and clinical-trial data [2][3]. Subcutaneous dosing carries the rodent bone and body-composition studies and is the dominant route in community use [4]. Intraperitoneal injection appears in rodent and ferret efficacy work [5]. Intranasal delivery shows roughly 20% bioavailability in a rodent note. Oral dosing applies only to engineered ipamorelin-derived analogs, not to ipamorelin itself, which is not orally bioavailable — covered in detail on the [ipamorelin oral](/oral) page. ## How much cjc-1295 ipamorelin should i take How much cjc-1295 ipamorelin should I take? This site cannot and does not answer that. There is no approved or trial-validated human dose for ipamorelin or for the CJC-1295 plus ipamorelin combination [3]. The community subcutaneous "stack" protocols circulating online have no peer-reviewed human dosing basis and must be treated as anecdotal, not as recommendations [3]. A 2020 andrology review discusses the gap between such marketed use and any approved indication for this class [10]. ## How to reconstitute cjc-1295 ipamorelin 5mg How to reconstitute cjc-1295 ipamorelin 5mg? Ipamorelin is supplied as a lyophilized (freeze-dried) powder, free base or acetate salt, and reconstituted with bacteriostatic water for research handling [2]. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction, and this site gives no volumes, concentrations, or dosing math for human use. --- A broadsheet dossier on the ipamorelin record — the failed human trial, the 2024 compounding rollback, and the WADA prohibition reported in plain ink; no clinic behind the masthead and nothing here dosed, compounded, prescribed, or sold.